Table 3.
Within-group differences after dose reduction or between 3 and 6 months of tamoxifen treatment
| Before and after dose reduction (n = 17) | Mean before dose reduction | Mean 3 months after dose reduction | Difference before and after dose reduction (95% CI) | P value (two-sided) |
|---|---|---|---|---|
| Health-related QOL | 74.3 | 82.5 | 8.2 (0.9-15.4) | 0.03 |
| Endocrine subscale 19 | 49.3 | 55.0 | 5.7 (−0.5-11.5) | 0.053 |
| Endocrine subscale 23 | 58.9 | 66.0 | NAa | 0.053 |
| 3 and 6 months of tamoxifen 20 mg use (n = 60) | Mean 3 months | Mean 6 months | Δ 6 months versus 3 months (95% CI) | P value (two-sided) |
|---|---|---|---|---|
| Health-related QOL | 82.6 | 81.9 | −0.6 (−2.8-1.5) | 0.55 |
| Endocrine subscale 19 | 56.2 | 56.7 | 0.5 (−1.4-2.4) | 0.61 |
| Endocrine subscale 23 | 68.0 | 68.5 | 0.5 (−1.9-2.8) | 0.71 |
CI, confidence interval; QOL, quality of life.
a
Wilcoxon signed rank test